Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999626 | 0.91 | BACE1 (0.79) | BACE1KCNH2 | |
| SCHEMBL1999628 | 0.91 | BACE1 (0.79) | BACE1KCNH2 | |
| SCHEMBL2519377 | 0.89 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL15418637 | 0.89 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL2519373 | 0.89 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL2520329 | 0.87 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL2520327 | 0.87 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL15418917 | 0.87 | BACE1 (0.69) | BACE1KCNH2 | |
| SCHEMBL15418695 | 0.87 | BACE1 (0.68) | BACE1KCNH2 | |
| SCHEMBL2526573 | 0.87 | BACE1 (0.69) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012446-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| US-8497264-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 3091/4885 |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.